These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32033488)

  • 1. Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein.
    Barkovits K; Kruse N; Linden A; Tönges L; Pfeiffer K; Mollenhauer B; Marcus K
    Cells; 2020 Feb; 9(2):. PubMed ID: 32033488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement.
    Paciotti S; Stoops E; François C; Bellomo G; Eusebi P; Vanderstichele H; Chiasserini D; Parnetti L
    Clin Chem Lab Med; 2021 Sep; 59(10):1653-1661. PubMed ID: 33957709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
    Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O
    Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.
    Kruse N; Persson S; Alcolea D; Bahl JM; Baldeiras I; Capello E; Chiasserini D; Bocchio Chiavetto L; Emersic A; Engelborghs S; Eren E; Fladby T; Frisoni G; García-Ayllón MS; Genc S; Gkatzima O; Heegaard NH; Janeiro AM; Kováčech B; Kuiperij HB; Leitão MJ; Lleó A; Martins M; Matos M; Mollergard HM; Nobili F; Öhrfelt A; Parnetti L; de Oliveira CR; Rot U; Sáez-Valero J; Struyfs H; Tanassi JT; Taylor P; Tsolaki M; Vanmechelen E; Verbeek MM; Zilka N; Blennow K; Zetterberg H; Mollenhauer B
    Neurobiol Aging; 2015 Sep; 36(9):2587-96. PubMed ID: 26093515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF Sample Preparation for Data-Independent Acquisition.
    Barkovits K; Tönges L; Marcus K
    Methods Mol Biol; 2019; 2044():61-67. PubMed ID: 31432406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deployment of Label-Free Quantitative Olfactory Proteomics to Detect Cerebrospinal Fluid Biomarker Candidates in Synucleinopathies.
    Lachén-Montes M; González-Morales A; Fernández-Irigoyen J; Santamaría E
    Methods Mol Biol; 2019; 2044():273-289. PubMed ID: 31432419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
    J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.
    Kruse N; Mollenhauer B
    Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid.
    Kruse N; Mollenhauer B
    J Immunol Methods; 2015 Nov; 426():70-5. PubMed ID: 26271436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
    Wang X; Yu S; Li F; Feng T
    Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
    Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
    J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.
    Llorens F; Kruse N; Schmitz M; Gotzmann N; Golanska E; Thüne K; Zejneli O; Kanata E; Knipper T; Cramm M; Lange P; Zafar S; Sikorska B; Liberski PP; Mitrova E; Varges D; Schmidt C; Sklaviadis T; Mollenhauer B; Zerr I
    Alzheimers Dement; 2017 Jun; 13(6):710-719. PubMed ID: 27870938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.
    Ishii R; Tokuda T; Tatebe H; Ohmichi T; Kasai T; Nakagawa M; Mizuno T; El-Agnaf OM
    PLoS One; 2015; 10(4):e0123162. PubMed ID: 25849645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    Mollenhauer B; Bowman FD; Drake D; Duong J; Blennow K; El-Agnaf O; Shaw LM; Masucci J; Taylor P; Umek RM; Dunty JM; Smith CL; Stoops E; Vanderstichele H; Schmid AW; Moniatte M; Zhang J; Kruse N; Lashuel HA; Teunissen C; Schubert T; Dave KD; Hutten SJ; Zetterberg H
    J Neurochem; 2019 Apr; 149(1):126-138. PubMed ID: 30125936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.